Commitments and Contingencies

3 Months Ended

Mar. 31, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

16. Commitments and Contingencies

Legal proceedings

In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. As of March 31, 2021, in the opinion of management, no claims meet the criteria to record a loss contingency.

Lease commitments

The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2027.

Maturities of lease liabilities:

Year ending December 31,	Operating Leases		Finance Leases
2021 (remaining nine months)	$	2,861	$	893
2022		3,498		6,165
2023		3,351		12,438
2024		2,758		—
2025		2,179		—
Thereafter		6,428		—
Total minimum lease payments		21,075		19,496
Less: amounts related to interest payments		3,260		3,902
Present value of minimum lease payments		17,815		15,594
Less: current accrued lease obligation		2,888		—
Obligations recognized	$	14,927	$	15,594

Purchase commitments

The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of March 31, 2021:

	Total		2021 (remaining nine months)		2022		2023		2024		2025		Thereafter
Purchase commitments	$	17,359	$	17,359	$	—	$	—	$	—	$	—	$	—
Total	$	17,359	$	17,359	$	—	$	—	$	—	$	—	$	—

Due to the termination of a supply agreement, the Company removed $59,700 of purchase commitments from its commitments and contingencies as of March 31, 2021.

In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years.  In September 2020, the Company signed an amendment to this agreement under which the Company is no longer obligated to purchase product from Rose nor pay the minimum fee.  The Company will pay Rose a compensation fee based on net revenue sold in Quebec for an estimated compensation fee of approximately $8,000 through 2023. As there is no firm commission fee commitment, it is excluded from the above schedule. Compensation fee expense is recorded as incurred.

In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 20), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales, with a minimum royalty of $493 per quarter. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule.

Other commitments

The Company has payments on the convertible notes (refer to Note 10), the Senior Facility (refer to Note 11), ABG finance liability and Portugal construction purchase commitments as follows:

	Total		2021 (remaining nine months)		2022		2023		2024		2025		Thereafter
Convertible notes, principal    and interest	$	319,535	$	13,893	$	13,893	$	291,749	$	—	$	—	$	—
Senior Facility, principal and    interest		56,533		4,029		52,504		—		—		—		—
ABG finance liability		7,500		1,500		1,500		1,500		1,500		1,500		—
Portugal construction    commitments		2,778		2,778		—		—		—		—		—
Total	$	386,346	$	22,200	$	67,897	$	293,249	$	1,500	$	1,500	$	—